Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CR Sanjiu Pharma Acquires Shenghuo Pharma for $280 Million

publication date: Jul 27, 2016
China Resources Sanjiu Pharma will pay $280 million to acquire Kunming Shenghuo Pharmaceutical Group, a TCM company. Shenghuo has three subsidiaries that interest Sanjiu: Shenghuo Pharma, Shenghuo Cosmetics and Shenghuo Import & Export. Shenghuo's hotel business is not included in the deal. Sanjiu is a listed subsidiary of state-owned company China Resources Pharma, which is expected to stage a $1 billion IPO in Hong Kong soon. More details....

Stock Symbol: (SHA: 000999)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital